Hong Kong Asia Medical Holding Limited (“Asia Medical”) today announced a strategic partnership with a $150 million investment from General Atlantic, a leading global growth equity firm. Asia Medical is a leading privately-owned Chinese healthcare services provider and hospital operator specializing in heart surgery and cardiology, which operates under the brand name ‘Asia Heart’. The strategic partnership marks the expansion of General Atlantic’s investment focus into the healthcare and biotechnology sector in China.

Founded in 1999 in Wuhan, Asia Medical currently operates two heart hospitals in Wuhan and Xinjiang, and co-manages four additional heart centers. The first Asia Heart hospital in Wuhan has become one of the top three heart hospitals in China based on volume of cardiovascular surgeries completed. This hospital not only serves patients from Hubei Province, but has also become the destination for heart-related diseases and surgeries for four neighboring provinces. In 2010, the company expanded its footprint with the acquisition of the Xinjiang hospital, which is now established as a top hospital in treating heart-related diseases in the province.

With a strong patient-centric philosophy and a top-notch medical and management team, Asia Medical’s continuous investment in clinical innovation, advanced data-driven, and digitalized medical process management allows the company to utilize modern treatment methods to address critical diseases. The hospitals under Asia Medical have also adopted an efficient dual-track management structure that separates clinical service from administrative work, which helps the company to drive excellence in hospital operation.

“We are proud that Asia Medical has established itself as a trusted medical services provider specializing in heart surgery and cardiology in China over the past 19 years,” said Mr. Tse Chun Ming, Founder and Chairman of Asia Medical. “We are excited to partner with General Atlantic and leverage the firm’s global healthcare expertise as we continue to provide high-quality healthcare services to a broad base of patients in China and beyond.”

According to data from China’s National Center for Cardiovascular Diseases, cardiovascular disease is the most prevalent chronic non-infectious disease in China and the leading cause of death. In a market dominated by public hospitals in China, Asia Medical has become one of the few private hospitals that has successfully established itself as a leading operator in the healthcare service space for cardiovascular.

“The healthcare industry in China has grown rapidly in recent years, with increased demand for healthcare services that specialize in the treatment of cardiovascular disease,” said Eric Zhang, Managing Director and Head of China at General Atlantic. “Asia Medical provides cutting-edge clinical solutions, combined with a highly dedicated founder and management team, and we are proud to partner with them as we expand our sector focus in China.”

This year, Asia Medical has opened a co-managed heart center in Hong Kong and completed an acquisition of a Japanese heart center. Its second hospital in Wuhan, Wuhan Asia General Hospital, will commence operation in November 2018. The hospital will operate several other departments including neurology and neurosurgery, pediatrics, obstetrics, and gynecology, which have strong synergies with its heart department to provide multi-specialty medical services. In its next phase of growth, Asia Medical plans to further develop its state-of-the-art hospital management systems and advanced medical technologies, including transcatheter aortic valve replacement. The company also intends to grow into a modern hospital group in cardiology space and expand internationally through organic growth and strategic acquisitions.

“With the increasing demand for high-end healthcare services in China, we are optimistic that medical groups with outstanding management will grow rapidly to meet the needs for consumption, technology, and service upgrade,” said Lefei Sun, Principal and Head of Healthcare for China at General Atlantic. “General Atlantic plans to continue to partner with visionary companies in the healthcare value chain in China and support them to grow into the leading companies in the industry.”

Drawing from 38 years of experience investing in over 300 global growth companies, General Atlantic partners with entrepreneurs and management teams who are building leading, high-growth businesses. The firm has USD $28 billion assets under management as of June 30, 2018 and focuses on investments across four sectors, including Consumer, Financial Services, Healthcare, and Technology, with support from the firm’s global team of experts. General Atlantic has deep expertise in the healthcare sector and is currently invested in leading companies, including Gingko Bioworks, KIMS Hospitals, and Landmark Health. The firm has been actively investing in China since 1999.

About Hong Kong Asia Medical Holding Limited

Hong Kong Asia Medical Holding Limited (“Asia Medical”), a leading privately-owned healthcare services provider and hospital operator specializing in heart surgery and cardiology, was founded in Wuhan, China, in 1999. Asia Medical’s mission is to grow Asia Heart, the brand name under which it operates, into a world-class healthcare services provider. Asia Medical currently has a network of two directly operated heart hospitals in Wuhan and Xinjiang and four co-managed heart centers in Mainland China and Hong Kong under the brand of “Asia Heart”, which provide a range of comprehensive medical services for the treatment of heart related diseases.

About General Atlantic

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 115 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. www.generalatlantic.com.[:zh]香港亚洲医疗股份有限公司（“亚洲医疗”）今日宣布，与全球领先的投资机构美国泛大西洋投资集团（General Atlantic）达成战略合作，由泛大西洋投资集团向亚洲医疗投资1.5亿美元。亚洲医疗是行业领先的民营医疗服务供应商及心血管疾病专科医院运营商，旗下医院均以“亚心”品牌运营。此项战略合作的达成，也标志着泛大西洋投资集团的投资范围，进一步扩大到中国医疗和生命科技行业。

亚洲医疗1999年在武汉成立，目前在武汉和新疆设有两家心血管医院，并联营管理四家心血管中心。就心血管外科手术数量而言，亚洲医疗在武汉设立的第一所亚心医院，已成为中国三大心血管病医院之一。除湖北省外，该医院还为四个周边省份的心血管疾病患者提供治疗和手术。2010年，亚洲医疗收购新疆医院，进一步扩大业务范围。该医院现在已经成为当地顶级的心血管专科医院。

亚洲医疗秉承以患者为中心的理念，并拥有一流的医疗及管理团队，在临床创新、先进的数据驱动和数字化医疗流程管理等方面持续投入，使其能够利用现代的医疗方法应对重大疾病。亚洲医疗旗下的医院还采用有效的双轨管理结构，将临床医疗与行政管理分离，在医院运营方面取得了卓越成果。

亚洲医疗创办人兼董事长谢俊明指出：“在过去的19年中，亚洲医疗始终专注于心血管手术和心血管疾病医疗服务，如今已成为在中国深受信赖的医疗服务供应商，对此我们深感自豪。我们很高兴能够与泛大西洋投资集团合作，借助该公司在全球医疗领域的专项资源，持续为中国及其他地区的患者提供高水平的医疗服务。”

中国国家心血管病中心的数据显示，心血管病是中国最常见的慢性非传染性疾病，也是导致患者死亡的主要原因。在以公立医院为主导的中国医疗市场中，亚洲医疗成为心血管疾病领域的顶级医疗机构之一，这在民营医院中是十分难得的。

泛大西洋投资集团董事总经理兼中国区负责人张弛表示：“近年来，中国的医疗健康行业发展迅速，对心血管疾病的专科医疗服务的需求也与日俱增。亚洲医疗不仅能够提供先进的临床解决方案，而且拥有高素质的创始人和管理团队。泛大西洋投资集团非常荣幸能够与亚洲医疗合作，进一步拓展我们在中国的行业重心。”

今年，亚洲医疗在香港开设了一家联营心血管中心，并完成了对一家日本心血管中心的收购。同时，亚洲医疗在武汉市设立的第二家医院——武汉亚心总医院，将于2018年11月正式开始运营。除心血管专科外，该院还将开设数个与心血管科具有极强协同性的医疗科室，如神经内外科、儿科、妇产科等，提供多项专业医疗服务。下一阶段，亚洲医疗计划继续发展顶尖的医院管理系统和先进的医疗技术，包括经导管主动脉瓣置换术等。未来，亚洲医疗计划逐步发展成为现代化的心血管医院集团，并通过有机增长和战略收购，拓展国际市场。

泛大西洋投资集团中国医疗行业负责人孙乐非表示：“中国对高端医疗服务的需求不断增长，我们看好拥有出色管理能力的医疗集团的发展前景。我们认为这些医疗集团将迅速成长，满足市场对消费、技术和服务升级的需求。泛大西洋投资集团将继续与中国医疗产业链中具有远见的企业开展合作，支持它们成长为行业中的龙头企业。”

泛大西洋投资集团拥有38年的投资经验，至今已在全球范围内投资了300多家成长型企业，并与行业领先的高增长型企业的企业家和管理团队保持合作。截至2018年6月30日，该公司管理资产达280亿美元。在全球专家团队的支持下，公司专注于四个领域的投资，包括消费类、金融服务类、医疗健康类和科技类。泛大西洋投资集团在医疗领域拥有深厚的专业知识，并为行业领先的医疗和生命科技企业提供投资，包括Gingko Bioworks、KIMS Hospitals、Landmark Health等。自1999年以来，该公司一直致力拓展中国市场，在中国地区积极展开投资业务。

关于香港亚洲医疗股份有限公司

香港亚洲医疗股份有限公司( “亚洲医疗”)于1999年在中国武汉成立，是一家行业领先的民营医疗服务供应商、心血管外科手术及心血管疾病专科医院运营商。亚洲医疗的使命是将旗下品牌“亚心”发展成为世界级的医疗服务供应商。亚洲医疗目前在武汉和新疆拥有两家直营心血管医院，在中国大陆和香港联营管理四所“亚心”品牌心血管中心，为心血管相关疾病的治疗提供全面的医疗服务。

关于泛大西洋投资集团

泛大西洋投资集团（“泛大西洋投资”）是一家全球领先的成长型私募股权投资公司，为成长型公司提供资金和战略支持。成立于1980年，泛大西洋投资分布全球各地的投资团队通力合作，结合独到的行业洞见、长期的投资期限以及对业务成长驱动力的深刻理解，在全球范围内与优秀的管理团队合作，共建卓越企业。泛大西洋投资拥有超过115位专业投资人士，分布在全球各大城市，包括纽约、格林威治、帕洛阿尔托、北京、上海、香港、伦敦、阿姆斯特丹、慕尼黑、孟买，墨西哥城、圣保罗和新加坡。更多信息，请访问：www.generalatlantic.com。